

ZNF304 antibody - N-terminal region
Rabbit Polyclonal Antibody
Catalog # AI11550**Specification**

ZNF304 antibody - N-terminal region - Product Information

Application	WB
Primary Accession	O9HCX3
Other Accession	NM_020657 , NP_065708
Reactivity	Human, Mouse, Rat, Pig, Horse, Bovine, Dog
Predicted	Human, Horse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	75kDa KDa

ZNF304 antibody - N-terminal region - Additional Information**Gene ID** 57343

Alias Symbol	MGC129703, MGC129704
Other Names	
Zinc finger protein 304, ZNF304	

Format

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage

Add 50 ul of distilled water. Final anti-ZNF304 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions

ZNF304 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

ZNF304 antibody - N-terminal region - Protein Information**Name** ZNF304 ([HGNC:13505](#))**Function**

Acts as a transcriptional regulator and plays a role in gene silencing (PubMed:24623306, PubMed:26081979). Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of several tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells (PubMed:24623306). Also required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells

(ESCs) by inducing trimethylation of 'Lys-27' of histone H3 (H3K27me3) (PubMed:24623306) in a Polycomb group (PcG) complexes-dependent manner. Associates at promoter regions of TSGs and mediates the recruitment of the corepressor complex containing the scaffolding protein TRIM28, methyltransferase DNMT1 and histone methyltransferase SETDB1 and/or the PcG complexes at those sites (PubMed:24623306). Transcription factor involved in the metastatic cascade process by inducing cell migration and proliferation and gain resistance to anoikis of ovarian carcinoma (OC) cells via integrin- mediated signaling pathways (PubMed:26081979). Associates with the ITGB1 promoter and positively regulates beta-1 integrin transcription expression (PubMed:26081979). Promotes angiogenesis (PubMed:26081979). Promotes tumor growth (PubMed:24623306, PubMed:26081979).

Cellular Location

Nucleus. Note=Associates with chromatin (PubMed:24623306)

Tissue Location


Expressed in undifferentiated embryonic stem cells (ESCs) (PubMed:24623306). Expressed strongly in colorectal cancers cells (CRCs) (PubMed:24623306). Expressed strongly in ovarian carcinoma (OC) tumor cell lines compared to non-transformed ovarian epithelial cells (at protein level) (PubMed:26081979). Expressed in lymphoid tissues, thyroid, adrenal gland, prostate, pancreas and skeletal muscles (PubMed:12051768).

ZNF304 antibody - N-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

ZNF304 antibody - N-terminal region - Images



WB Suggested Anti-ZNF304 Antibody Titration: 0.2-1 µg/ml

ELISA Titer: 1:312500
Positive Control: OVCAR-3 cell lysate